Follow us on:

Linkedin Facebook

EDX Medical publishes Annual Report and Notice of AGM

EDX Medical Group plc
[shareaholic app="share_buttons" id_name="post_below_content"]

EDX Medical Group Plc (AQSE: EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, heart disease and infectious diseases, has announced that its annual general meeting (AGM) will be held at Mezzanine Room, 1 Wimpole Street, Westminster, London, W1G 0AE on 30 September 2024 at 2:00 p.m.

The annual report and financial statements for the year ended 31 March 2024, Notice of AGM and Form of Proxy will be posted today, 4 September 2024, to eligible shareholders.

31Mar24-EDX-Medical-Group-plc-ARA-finalDownload

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical Group plc

EDX Medical strengthens shareholder value by cancelling legacy warrants

EDX Medical Group (LON:EDX) cancels 5.37 million warrants, enhancing stability and reducing potential dilution for shareholders amidst robust growth.
EDX Medical Group plc

EDX Medical receives support from high net worth, experienced healthcare investor

EDX Medical Group (AQSE:EDX) secures a £300,000 strategic investment from a Saudi healthcare investor to expand its digital diagnostic products.
EDX Medical Group plc

EDX Medical Chairman and Founder provide shareholder update

EDX Medical

EDX Medical appoints Eric Vick as Chief Commercial Officer

EDX Medical Group plc

EDX Medical signs distribution agreement with Caris Life Sciences

EDX Medical Group plc

EDX Medical partners with Oxford University to enhance cancer drug safety testing

EDX Medical Group plc, in collaboration with The University of Oxford, has announced a major advancement in cancer testing to enhance chemotherapy safety and efficacy.

Latest interviews

View all interviews 

Company Presentations

View all Company Presentations

Brokers Talk

View all Broker Talk

FTSE 100 News

Search

Search

Green News

View all Sustainable sectors, Plcs and news  

Q&A's

View all Question and Answers

Funds

View all Funds, Market Insights and news

UK Broker Ratings

Hardman & Co

Don't Miss Our News Alerts

Subscribe Free

Find us on:

Linkedin Facebook

Useful links

Disclaimer

You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular stock, share, security, portfolio of securities, transaction, investment strategy, or other matter. We openly disclose that we and our contributors may have interests in investments and/or providers of services referred to within the website and that we receive remuneration from certain of the companies referred to on this website.

© 2024 – DirectorsTalk Interviews. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.